LONDON, September 10, 2025 – Coulter Partners, the global expert building leadership teams for Health, Science and Technology innovation businesses, successfully completed a search assignment for the Cell and Gene Therapy Catapult (CGT Catapult) and is pleased to announce the placement of Dr. Ed Samuel as Chief Operations Officer (COO).CGT Catapult is an independent technology and innovation organization specializing in the advancement of the cell and gene therapy industry through powerful collaborations.Ed Samuel has over 20 years of experience in advanced therapies, including…
Recently, Medicilon officially obtained the Good Laboratory Practice (GLP) certification certificate issued by Mexico, a member country of the OECD. In addition, we successfully passed GLP on-site inspections conducted by Hungary.
Following recent FDA and PMDA GLP audits, this achievement reaffirms that Medicilon’s preclinical research quality continues to meet the highest international standards.
🌍 Committed to Compliance Management, Empowering Global Drug Innovation
OECD GLP certification is recognized globally as the gold standard in preclinical safety evaluation for its rigor,…
Creative Biolabs delivers customized preparation solutions to solve the tough challenges facing membrane protein discovery, ensuring to yield proteins that remain functional and ready for downstream applications. Researchers have been fascinated by membrane proteins for years: A 2016 paper in Nature Methods shed light on the stubborn technical barriers of isolating these proteins in their native form, and more recently, in 2023, a PNAS study demonstrated how advanced protocols can unravel structural details.Yet the cruel reality is that not that many labs hold the techniques for…
London, UK, 8 September 2025 – Myricx Bio (‘Myricx’), a UK-based biotech company focusing on the discovery and development of a completely novel class of payloads for antibody-drug conjugates (ADCs), is pleased to announce the appointment of Jonathon Marks-Bluth, Ph.D., to its leadership team in the newly created position of VP, Business Development.
Based at Myricx’s London, UK facilities, Jonathon joins the company at a time when its multiple N-myristoyltransferase inhibitor (NMTi)-ADC programs are advancing towards clinical development and where partnership options are being explored.…
• Oversubscribed £50m Series B led by SV Health Investors’ Dementia Discovery Fund, alongside other new investors British Business Bank, M Ventures, Novartis Venture Fund and Criteria Bio Ventures, together with existing investors Omega Funds and Brandon Capital
• The financing will enable NRG Therapeutics to deliver clinical proof of concept in ALS/MND with NRG5051, a first-in-class, oral inhibitor of the mitochondrial permeability transition pore (mPTP)
• The mPTP is a well-established driver of mitochondrial dysfunction, inflammation, and neuronal death in neurodegenerative diseases. NRG’s…
Pioneer Group, a specialist in life science infrastructure and venture building, has once again teamed up with global biopharmaceutical company AbbVie to launch a Golden Ticket programme designed to accelerate companies developing novel, transformational therapies and innovations for immunology, oncology, neurology, eye care, aesthetics, or other specialities including obesity, GI and hepatology.
The 2025 Golden Ticket Programme offers the opportunity for an early-stage biotech company to secure one year of funding for lab space, a £50,000 grant, mentorship and scientific expertise to support…
Bind Research and Twig Bio join LBIC at the Apex in King’s Cross, bringing LBIC’s space to over 50% occupancy just six months after launch.
Bind Research becomes The Apex’s first non-profit tenant, recently awarded major UK Government and partner funding.
LONDON, UK, 3rd September 2025: London BioScience Innovation Centre (LBIC) has welcomed two new tenants, Bind Research and Twig Bio, to its Apex facility in King’s Cross, reaching more than half its capacity within six months. The milestone validates LBIC’s growth strategy of providing state-of-the-art, fully fitted, grow-on laboratory…
Welcome to this month's eNews
Looking Forward to a Golden Autumn
Tony Jones, CEO, One Nucleus
Many look forward to the autumnal colours arriving as the seasons move along from summer breaks and a recharging of batteries in the sun. It’s no different at One Nucleus, where our team is excited to welcome its network back to our upcoming opportunities to engage, alongside some new initiatives and support supplier deals to roll out that have been ripening over the summer.
The financing environment remains challenging for many, as we are all aware, so one hopes the golden colours…
Pioneer Group, a specialist in life science infrastructure and venture building, has launched a new Accelerator Programme for early-stage life science companies targeting unmet needs in the management of chronic conditions.
Funded by the Innovate UK Biomedical Catalyst, in collaboration with the Medical Research Council, the Accelerator has been designed to support UK start-ups in the initial phases of their development.
Pioneer is inviting applications from companies targeting unmet needs in disease prevention or the proactive management, whether targeting a single health condition or…
Cambridge, UK: o2h Technology, a business vertical of the o2h Group, is delighted to announce the launch of the fourth edition of its Tech Kickstarter Competition. First launched in 2023, the initiative continues to support innovative seed and early-stage companies by helping them bring their ideas to life with end-to-end MVP, web, and mobile app development needs.Building on the success of earlier editions, the competition has already established itself as a catalyst for innovative seed and early-stage ventures. To date, it has attracted over 70 startup applications, with 9 winners selected…